natgillin/translations-raw huggingface dataset:
In addition, the company that markets MabThera will also submit reports from studies on the long- term safety of MabThera.
Peale selle esitab MabThera turustaja aruanded MabThera pikaajalise ohutuse uuringute kohta.
In addition, the company that markets Oncaspar will complete two more studies on the safety and effectiveness of Oncaspar, which will help further clarify the benefits and risks of this medicine in adults and in newly diagnosed patients.
Lisaks korraldab Oncaspari turustav ettevõte kaks täiendavat uuringut Oncaspari ohutuse ja efektiivsuse kohta, mis aitavad selgitada ravimi kasulikkust ja riske täiskasvanutel ning esmadiagnoosiga patsientidel.
In addition, the company that markets Opsumit will send educational material to patients and healthcare professionals with information on the precautions to be taken when using Opsumit.
Lisaks saadab Opsumiti turustav ettevõtte patsientidele ja tervishoiutöötajatele teabematerjali ettevaatusabinõudega, mida peab Opsumiti manustamisel järgima.
In addition, the company that markets Perjeta will carry out two studies to assess the effects of using Perjeta and trastuzumab together with two different types of cancer medicine, in patients with HER2- positive breast cancer that is metastatic or has come back after treatment.
Lisaks korraldab Perjetat turustav ettevõte kaks uuringut, et hinnata koos kasutatavate Perjeta ja trastusumaabi toimet kahe muud tüüpi vähiravimi toimega HER2-positiivse rinnavähiga patsientidel, kelle vähk on metastaatiline või pärast ravi taastekkinud.
In addition, the company that markets Prolia will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.
Lisaks varustab Prolia turustaja patsiendid teabekaardiga, milles neid teavitatakse lõualuu osteonekroosi riskist ning soovitatakse neil sümptomite ilmnemisel arsti poole pöörduda.
In addition, the company that markets Raplixa will ensure that all surgeons using Raplixa are provided with educational material to inform them of the risk of air or gas embolism and how to use the spray correctly.
Lisaks varustab Raplixat turustav ettevõte kõik Raplixat kasutavad kirurgid teabematerjaliga õhk- ja gaasemboolia tekke riski ja pihusti õige kasutamise kohta.
In addition, the company that markets Ravicti will set up a registry of patients to obtain further information on the long-term benefits and safety of the medicine.
Lisaks koostab Ravicti turustaja patsiendiregistri, et koguda teavet ravimi pikaajalise kasulikkuse ja ohutuse kohta.
In addition, the company that markets Relvar Ellipta will conduct further studies to investigate the risk of pneumonia with this medicine in comparison with other COPD and asthma medicines.
Lisaks teeb Relvar Elliptat turustav ettevõte täiendavaid uuringuid, milles käsitletakse ravimiga kaasnevat kopsupõletiku riski võrreldes kroonilise obstruktiivse kopsuhaiguse ja astma muude ravimitega.
In addition, the company that markets Remsima will provide educational material to doctors who are expected to prescribe the medicine in adults and children, including information on the safety of the medicine and an alert card to be given to patients.
Lisaks varustab Remsimat turustav ettevõte kõik ravimit täiskasvanutele ja lastele eeldatavasti määravad arstid ravimiohutuse teabega ning patsienti hoiatuskaardiga.
In addition, the company that markets Revinty Ellipta will conduct further studies to investigate the risk of pneumonia with this medicine in comparison with other COPD and asthma medicines.
Lisaks teeb Revinty Ellipta turustaja täiendavaid uuringuid, milles käsitletakse ravimiga kaasnevat kopsupõletiku riski võrreldes kroonilise obstruktiivse kopsuhaiguse ja astma muude ravimitega.
In addition, the company that markets Revolade will ensure that doctors in all Member States who will prescribe the medicine are provided with educational materials reminding them how the medicine should be used and of the medicine’s possible side effects such as liver problems, thromboembolic complications and the recurrence of bleeding.
Lisaks tagab Revolade turustaja, et kõikidele Revoladet määravatele liikmesriikide arstidele antakse teabematerjalid, mis sisaldavad teavet ravimi õige kasutamise ja võimalike kõrvalnähtude kohta, nagu maksaprobleemid, trombemboolilised tüsistused ja verejooksu taasteke.
In addition, the company that markets Senshio will carry out an observational study to further investigate long-term potential risks such as endometrial hyperplasia, stroke and venous thromboembolism.
Lisaks viib Senshiot turustav ettevõte läbi täiendava vaatlusuuringu selliste võimalike pikaajaliste riskide kohta nagu endomeetriumi hüperplaasia, insuldi ja veeni trombemboolia risk.
In addition, the company that markets Sevelamer carbonate Zentiva will make sure that educational material is available in all Member States for patients and healthcare professionals.
Lisaks annab ravimi Sevelamer carbonate Zentiva turustaja kõigis liikmesriikides teabematerjalid patsientidele ja tervishoiutöötajatele.
In addition, the company that markets Soliris will ensure that distribution of the medicine occurs only after checking that the patient has been vaccinated appropriately.
Lisaks tagab Solirise tootja, et ravimit väljastatakse alles pärast seda, kui on kontrollitud patsiendi asjakohast vaktsineerimist.
In addition, the company that markets Thalidomide Celgene will set up a pregnancy prevention programme in each Member State.
Peale selle algatab Thalidomide Celgenet turustav ettevõte kõigis liikmesriikides raseduse ennetamise programmi.
In addition, the company that markets Vizamyl will provide access to a training course for all nuclear- medicine physicians expected to use this product in the European Union, in order to ensure accurate and reliable reading of the PET scan images.
Lisaks võimaldab Vizamyli turustav ettevõte kõigil nukleaarmeditsiini arstidel, kes seda ravimit Euroopa Liidus kasutada võivad, osaleda koolituskursusel, et tagada PET-kihtülesvõtete täpne ja usaldusväärne hindamine.
In addition, the company that markets Volibris has agreed with EU Member States on systems to control the distribution of Volibris.
Lisaks on Volibrise tootja leppinud Euroopa Liidu liikmesriikidega kokku Volibrise turustamise jälgimise süsteemi.
In addition, the company that markets Xgeva will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.
Lisaks tagab Xgeva turustaja kaardi, milles teavitatakse patsiente lõualuu osteonekroosi riskist ning soovitatakse neil sümptomite ilmnemisel pöörduda oma arsti poole.
In addition, the company that markets Xultophy will provide educational materials for healthcare professionals, explaining how to use the medicine safely, so as to reduce the risk of medication errors.
Lisaks varustab Xultophyt turustav ettevõte tervishoiuspetsialistid teabematerjaliga, mis sisaldab teavet ravimi ohutu kasutamise kohta, et vähendada ravivigade riski.
In addition, the company will carry out a study in patients with myelodysplastic syndromes to gather further safety data, as well as a safety study in patients with newly diagnosed multiple myeloma not eligible for transplant.
Lisaks korraldab ettevõte täiendavate ohutusandmete kogumiseks müelodüsplastiliste sündroomidega patsientide uuringu, samuti ohutusuuringu hulgimüeloomi esmadiagnoosiga patsientidel, kellele ei saa luuüdi siirata.
In addition, the company will carry out a study investigating extended treatment intervals with Eylea in diabetic macular oedema, as well as a study looking at the effects of Eylea treatment when given on an as- needed basis in wet AMD.
Ettevõte viib läbi ka uuringu Eylea pikaajalise kasutamise kohta diabeedist tingitud makulaarse ödeemi korral ning Eylea vajaduspõhise kasutamise uuringu AMD märja vormi korral.
In addition, the company will carry out two further studies on the benefits of the medicine and a safety study in a larger population of HL and sALCL patients.
Peale selle viib ettevõte läbi kaks täiendavat uuringut ravimi kasulikkuse ja ohutuse kohta Hodgkini lümfoomi ja süsteemse anaplastilise suurrakklümfoomiga patsientide suuremas populatsioonis.
In addition, the company will maintain a patient registry to provide further data on long-term safety and the way the medicine is used in practice.
Lisaks loob tootja patsiendiregistri, et koguda lisaandmeid ravimi pikaajalise ohutuse ja praktilise kasutamise kohta.
In addition, the company will provide patients and carers with educational materials to ensure that Strensiq is used correctly and to minimise the risk of medication errors.
Lisaks varustab ettevõte patsiendid ja hooldajad teabepakmega, et tagada Strensiqi õige kasutamine ja vähendada ravivigade riski.
In addition, the company will provide the final results of the studies with Keytruda to confirm the long- term benefits of the medicine.
Ka esitab ettevõte ravimi pikaajalise kasulikkuse kinnitamiseks Keytruda uuringute lõpptulemused.
In addition, the company will provide the results of studies to try to further characterise those patients who respond better to Vectibix.
Lisaks esitab tootja selliste uuringute tulemused, milles selgitatakse senisest täpsemini, mis patsiendid reageerivad Vectibixi-ravile paremini.
In addition, the corresponding frequency category for each ADR is based on the CIOMS III convention and is defined as: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from available data).
Lisaks põhineb iga kõrvaltoime sageduskategooria CIOMS III konventsioonil ja on määratletud järgmiselt: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10 000 kuni < 1/1000); väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
In addition, the corresponding frequency category for each ADR is based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000).
Lisaks kasutati iga kõrvaltoime jaoks vastavat sageduse määratlust, mis põhineb järgmisel konventsioonil: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10000 kuni < 1/1000); väga harv (< 1/10000).
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Lisaks põhineb iga kõrvaltoime vastav esinemissageduse kategooria järgmisel konventsioonil (CIOMS III): väga sage (≥1/10); sage (≥1/100 kuni <1/10); aeg-ajalt (≥1/1000 kuni <1/100); harv (≥1/10 000 kuni <1/1000); väga harv (<1/10 000);teadmata (ei saa hinnata olemasolevate andmete alusel).
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Lisaks põhinevad vastavad esinemissageduste kategooriad järgmisele konventsioonile: väga sage (≥1/10), sage (≥1/100 kuni <1/10), aeg-ajalt (≥1/1000 kuni <1/100), harv (≥1/10 000 kuni <1/1000), väga harv (<1/10 000).
In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Kõrvaltoimete esinemissageduse kategooriad on määratletud järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000), teadmata (ei saa hinnata olemasolevate andmete alusel).
In addition, the corresponding frequency category is provided using the following convention: Very common ( 1/10); Common ( 1/100 to < 1/10); Uncommon ( 1/1,000 to < 1/100); Rare ( 1/10,000 to < 1/1,000); Very rare (< 1/10,000).
Peale selle on esinemissageduse kategooriad liigitatud järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000).
In addition, the corresponding frequency category using the following convention (CIOMS III) is also provided for each adverse drug reaction: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known: frequency cannot be estimated from the available data.
Lisaks on iga kõrvaltoime kohta toodud esinemissageduse kategooria, kasutades järgnevat klassifikatsiooni (CIOMS III): väga sage (≥1/10), sage (≥1/100 kuni <1/10), aeg-ajalt (≥1/1000 kuni <1/100), harv (≥1/10 000 kuni <1/1000), väga harv (<1/10 000); teadmata: ei saa hinnata olemasoleate andmete alusel..
In addition, the decongestant efficacy of Aerinaze tablets, as measured by nasal stuffiness/congestion, was significantly greater than desloratadine alone over the 2-week treatment period.
Lisaks, 2-nädalase raviperioodi jooksul oli Aerinaze’i tablettide veresooni ahendav toime, mida mõõdeti ninakinnisuse/kongestiooni alusel, märkimisväärselt suurem kui desloratadiinil üksinda.
In addition, the development of antibodies against NovoSeven and FVII has been associated with overdose in one patient with factor VII deficiency.
Lisaks on ühte VII faktori puudulikkusega patsiendi üleannustamise juhtu seostatud NovoSeven’i ja VII hüübimisfaktori vastaste antikehade tekkega.
In addition, the difference in the percentage of patients demonstrating ≥ 20% improvement in PANSS total score at Week 26 between the two treatment groups was numerically similar.
Lisaks sellele olid kahes ravirühmas arvuliselt sarnased ka protsentuaalsed erinevused patsientide hulgas, kellel 26. nädalal täheldati PANSS-i skoori paranemist ≥20%.
In addition, the difference in the percentage of patients demonstrating ≥ 20% improvement in PANSS total score at Week 26 between the two treatment groups was numerically similar.
Lisaks sellele olid kahes ravirühmas arvuliselt sarnased ka protsentuaalsed erinevused patsientide hulgas, kellel nädalal 26 täheldati PANSS-i skoori paranemist ≥20%.
In addition, the disproportionality analyses scores in Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and VigiBase databases suggests a potential association between aripiprazole and hiccups.
Aripiprasooli võimalikule seosele luksumisega viitavad ka USA toidu- ja ravimiameti (FDA) kõrvaltoimete kogumise süsteemis (FAERS) ja andmebaasis VigilBase tehtud teatiste ebaproportsionaalsuse hindamise tulemused.
In addition, the dulaglutide molecule was engineered to prevent the Fcγ receptor-dependent immune response and to reduce its immunogenic potential.
Lisaks sellele on dulaglutiidi molekuli töödeldud nii, et ei teki Fcγ retseptorite poolt vahendatud immuunvastust ja on vähenenud selle immunogeene potentsiaal.
In addition, the efficacy, safety and tolerability of Resolor in male patients with chronic constipation were evaluated in a 12-week, multi-centre, randomised, double-blind, placebo–controlled study (N=370).
Peale selle hinnati Resolori efektiivsust, ohutust ja talutavust kroonilise kõhukinnisusega meespatsientidel 12-nädalases mitmekeskuselises, randomiseeritud, topeltpimedas, platseebo- kontrolliga uuringus (N = 370).
In addition, the film coating contains the following inactive ingredients: poly(vinyl alcohol), macrogol 3350, talc (E553b), titanium dioxide (E171), iron oxide red (E172), and iron oxide black (E172).
Lisaks on õhukeses polümeerikattes polüvinüülalkohol, makrogool 3350, talk (E553b), titaandioksiid (E171), punane raudoksiid (E172) ja must raudoksiid (E172).
In addition, the following adverse reactions were reported during clinical trials with GlaxoSmithKline’s other combined hepatitis A and hepatitis B vaccines (given as a 3 or 4 dose schedule)
Lisaks on kliiniliste uuringute käigus teatatud järgmistest kõrvaltoimetest GlaxoSmithKline’i teise kombineeritud hepatiit A ja hepatiit B vaktsiiniga (manustatakse kas 3 või 4 annuselise skeemi järgi)
In addition, the following side effects have been identified during post-marketing experience.
Lisaks tuvastati turuletuleku järgselt järgmisi kõrvaltoimeid.
In addition, the following side effects have been seen after patients have taken ZYPREXA orally.
Lisaks eelnevale on ZYPREXA’t suukaudselt manustanud patsientidel täheldatud järgmisi kõrvaltoimeid:
In addition, the incidences of specific tumours in Raptiva patients were in line with those observed in control psoriasis populations.
Lisaks sellele oli spetsiifiliste kasvajate tekkesagedus Raptiva-patsientidel samaväärne tekkesagedusega psoriaasipatsientidest võrdlusrühmas.
In addition, the MAH should discuss any further outcome data on the combination of bevacizumab + erlotinib in this indication (e.g. data from the ongoing ACCRU
Lisaks peab müügiloa hoidja läbi arutama kõik täiendavad lõpptulemuse andmed, mis on saadud bevatsizumabi + erlotiniibi kasutamisel antud näidustusel (nt andmed käimasolevast uuringust ACCRU, NCT number NCT01532089)
In addition, the MAH will submit the second interim safety analysis of the phase III study JGDJ.
Lisaks peab müügiloa hoidja esitama 3 faasi uuringu JGDJ teise ohutuse vaheanalüüsi aruande.
In addition, the Patient Card explains the need for monitoring of liver function and educates the patient on the importance of adherence to their monthly blood tests
Lisaks selgitab patsiendikaart maksafunktsiooni jälgimise vajadust ja teavitab patsienti tema igakuiste vereanalüüside tegemisest kinnipidamise olulisusest.
In addition, the pharmacokinetic-pharmacodynamic models show no exposure-effect relationship, with an estimated QTcF mean change of –6.4 ms (upper confidence interval –0.9 ms) at Cmax for the 60 mg group.
Ka farmakokineetilised/farmakodünaamilised mudelid ei näita plasmakontsentratsiooni ja toime vahelist seost, sest hinnanguline QTcF keskmine muutus Cmax-i korral 60 mg rühmas oli -6,4 ms (usaldusvahemiku ülemine piir -0,9 ms).
In addition, the pharmacokinetics of weight-based doses of levofloxacin administered by inhalation once daily for 14 days in paediatric patients with CF (≥ 6 to < 12 years old, n = 14 and
Lisaks sellele uuriti uuringus 206 kaalupõhiste, 14 päeva jooksul üks kord ööpäevas inhaleerides manustatud levofloksatsiini annuste farmakokineetikat tsüstilise fibroosiga lastel (vanuses
In addition, the possibility of QTc prolongation and Torsades de pointes should be considered.
Lisaks tuleb arvestada QTc pikenemise ja torsade de pointes’i võimalusega.
In addition, the post-marketing reports with Oncaspar that include spontaneous reports as well as serious adverse events from clinical studies.
Lisaks Oncaspari turuletulekujärgsed teated, mis sisaldavad spontaanseid teateid ja raskeid kõrvaltoimeid kliinilistest uuringutest.
In addition, the powder will dissolve more readily if both vials are first allowed to reach room temperature (15°C – 25°C).
Lisaks lahustub pulber kergemini, kui mõlemal viaalil on lastud soojeneda toatemperatuurini (15 °C...25 °C).
In addition, the proper function of your liver and your kidneys will be checked.
Samuti kontrollitakse teie maksa- ja neerufunktsiooni.
In addition, the results confirmed the ability of Silgard to protect against lesions and HPV infection in 24- to 45-year-old women.
Lisaks kinnitasid tulemused Silgardi võimet kaitsta 24–45-aastasi naisi kahjustuste ja papilloomiviiruse nakkuse eest.
In addition, the results indicated that Jardiance treatment was associated with a beneficial fall in body weight and blood pressure.
Lisaks osutasid tulemused, et Jardiance raviga kaasnes kehakaalu ja vererõhu kasulik langus.
In addition, the results indicated that the combination was associated with a beneficial decrease in body weight and blood pressure.
Lisaks näitasid tulemused, et kombinatsioonraviga kaasnevad kehakaalu ja vererõhu kasulik langus.
In addition, the risk of seizure may be increased in patients receiving concomitant medicinal products that lower the seizure threshold.
Lisaks võib krambihoogude risk tõusta patsientidel, kes saavad samaaegselt krambiläve alandavaid ravimeid.
In addition, the safety of the medicine was considered acceptable.
Lisaks peeti ravimi ohutust vastuvõetavaks.
In addition, the usefulness of Amyvid in predicting the development of Alzheimer’s disease in patients with memory problems or in monitoring patients’ response to treatment has not been established.
Peale selle ei ole selge Amyvidi kasutatavus Alzheimeri tõve kulu prognoosimisel mäluprobleemidega haigetel või patsientide ravivastuse jälgimisel.
In addition, the usefulness of Neuraceq in predicting the development of Alzheimer’s disease in patients with memory problems or in monitoring patients’ response to treatment has not been established.
Lisaks ei ole tuvastatud Neuraceqi kasulikkust mäluprobleemidega patsientide Alzheimeri tõve arengu prognoosimisel ja patsientide ravivastuse jälgimisel.
In addition, the usefulness of Vizamyl in predicting the development of Alzheimer’s disease in patients with memory problems or in monitoring patients’ response to treatment has not been established.
Lisaks ei ole tuvastatud Vizamyli kasulikkust mäluprobleemidega patsientide Alzheimeri tõve arengu prognoosimisel ja patsientide ravivastuse jälgimisel.
In addition, there are certain signs and symptoms that you should look out for yourself.
Lisaks on teatud nähud ja sümptomid, mille suhtes peate ise tähelepanelik olema.
In addition, there have been few reports (<1%), some fatal, of subjects presenting with seizures and radiological evidence of reversible posterior leukoencephalopathy syndrome (RPLS).
Lisaks on mõnedel juhtudel (<1%) teatatud isikutest, kellel esinesid mõnikord surmaga lõppenud krambid ja radioloogiliselt kinnitust leidnud posterioorse reversiibelse leukoentsefalopaatia sündroom (reversible posterior leukoencephalopathy syndrome, RPLS).
In addition, there have been reported cases of burns, including second degree burns, in patients treated with capsaicin patches.
Lisaks on kapsaitsiiniplaastritega ravitavatel patsientidel teada antud põletusjuhtudest, sh teise astme põletustest.
In addition, there is a potential for a pharmacodynamic interaction to occur during co- administration due to additive renal effects.
Lisaks esineb potentsiaal farmakodünaamiliseks koostoimeks samaaegse manustamise puhul aditiivsete renaalsete toimete tõttu.
In addition, there is evidence indicating that the vaccine can protect against different strains of H5N1 virus.
Lisaks näitasid andmed, et vaktsiin on võimeline kaitsma H5N1 viiruse erinevate tüvede eest.
In addition, there is experimental evidence that Defibrotide may protect the cells lining blood vessels.
Samuti on katsetega tõendatud, et defibrotiid võib kaitsta veresoonte epiteeli rakke.
In addition, there was a statistically significant effect on 24 week confirmed disability progression in Zinbryta treated patients with a hazard ratio 0.24 [95% CI: 0.09, 0.63].
Lisaks esines statistiliselt märkimisväärne toime 24. nädalal kinnitatud puude progresseerumisele Zinbryta’ga ravitud patsientidel riskisuhtega 0,24 [95% CI: 0,09; 0,63].
In addition, there was no statistically significant increased risk of this adverse event during the 0-30 day follow-up period compared with a concurrent control group of infants who received DTaP, but not RotaTeq (n=62,617, 12,339 person-years of follow-up).
Lisaks ei olnud statistiliselt olulist suurenenud riski selle kõrvaltoime tekkeks 0…30-päevase järelkontrolli perioodi jooksul, võrreldes kontrollrühmaga, kuhu kuulusid lapsed, kes said teist DtaP vaktsiini, mitte RotaTeqi (n = 62 619; 12 339 inimaastat järelkontrolli).
In addition, there were no major safety concerns with Enurev Breezhaler, with side effects being similar to other anticholinergic bronchodilator medicines.
Samuti puudusid Enurev Breezehaleril suured ohutusprobleemid, sest ravimi kõrvalnähud on sarnased teiste antikolinergiliste bronhodilataatorite kõrvalnähtudega.